Wannabe,
Quote:
Originally Posted by wannabe
Is a "trend" in beneficial results less impressive than regular stastically significant results? That word "trend" worries me.
|
These days, when a drug company wants to show some kind of positive result for a MS medication, it hires the Cleveland Clinic to run the trial !
I agree....the word "trend" is troublesome...if you can't statistically prove something, using this word is a nice alternative. I also notice how they "gloss over" the site reaction results from the higher dosage....."Some features of injection site reactions and immediate postinjection reactions were more common and severe with the higher dose." Lipoatrophy can be a big problem for many patients using Copaxone so why didn't they elaborate more on this by giving more detail and percentages?
Many of us have read what the Cochrane Group's opinion of Copaxone states...not effective in the treatment of MS.... makes you wonder why they are doing an open label trial by doubling the dose. I also would like to know if by doubling the dosage, the patient has to pay double the price!!
I'm thinking this is a Teva marketing department's attempt to bolster the market share of Copaxone in the very lucrative MS drug market.
Harry